AEON Biopharma | SCHEDULE 13D: Others
AEON Biopharma | SCHEDULE 13G: Others
AEON Biopharma | SCHEDULE 13G: Others
AEON Biopharma | PRE 14A: Preliminary proxy statements relating to merger or acquisition
AEON Biopharma | SCHEDULE 13G: Others
AEON Biopharma | 8-K: Current report
AEON Biopharma | 424B5: Prospectus
AEON Biopharma | 8-K: Current report
AEON Biopharma | 424B5: Prospectus
AEON Biopharma | 8-K: Current report
AEON Biopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Blue Owl Capital Holdings LP(8.45%)
AEON Biopharma | 424B3: Prospectus
AEON Biopharma | 8-K: AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
AEON Biopharma | 10-Q: Q3 2024 Earnings Report
AEON Biopharma | 8-K: Current report
AEON Biopharma | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Director PALMISANO ROBERT J
AEON Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Sy Jennifer
AEON Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Carter Eric G
AEON Biopharma | 4: Statement of changes in beneficial ownership of securities-Director FISCHER JOST
AEON Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Forth Marc